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Unfolded protein responseThe endoplasmic reticulum (ER) is responsible for many housekeeping functionswithin the cell and is an impor-
tant site for pathways that regulates its state of homeostasis. When cellular states perturb ER functions, a
phenomenon termed “ER stress” activates a number of pathways to counteract the associated damages; these
pathways are together called the unfolded protein response (UPR). The UPR has a dualistic function; it exists
to alleviate damage associatedwith ER stress, however, if this is not possible, then it signals for cell death through
apoptosis. Cancer cells are shown to be very resilient under extreme environmental stress and an increasing
number of studies have indicated that this may be largely due to an altered state of the UPR. The role of ER stress
and the UPR in cancer is still not clear, however many components are involved and may prove to be promising
targets in future anti-cancer therapy. This article is part of a Special Issue entitled: Calcium Signaling inHealth and
Disease. Guest Editors: Geert Bultynck, Jacques Haiech, Claus W. Heizmann, Joachim Krebs, and Marc Moreau.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The optimum state of a cell is necessary for survival and is achieved
through a consistent and sustained level of homeostasis. The challenge,
however, lies in the fact that the cellular environment is constantly
undergoing change, disrupting the internal equilibrium of the cell. To
restore this balance cells have evolved numerousways to adapt to envi-
ronmental stress and, in cases where the damage is too great, ways to
remove the diseased cells, preventing toxicity.se 1; ATF4, activating transcrip-
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alak).
ights reserved.The endoplasmic reticulum (ER) is a major organelle housing many
cellular functions and is therefore an important site for maintaining ho-
meostasis. When pathways within the ER are disturbed, such as ones
that regulate protein folding, post-translational modiﬁcations, lipid
and steroid synthesis, gene expression, cellularmetabolism and calcium
signaling, ER functions become overwhelmed and the accumulation of
misfolded proteins within the ER lumen ultimately leads to ER stress
[1]. As a result, the ER launches various coping mechanisms to alleviate
the damage, allowing the cell to adapt to the environmental stress. On
the other hand, if the recovery of cellular adaptation is not achieved
prolonged ER stress triggers apoptosis [2]. Emerging evidence has
come to suggest a third pathway, one which allows cells to survive ex-
treme environmental insults and evade cell death through up-
regulation of ER adaptive measures [3]. The result is manifested at the
organismal level as a disease or disorder and in particular, cancer,
which has uniquemodiﬁcations that allow it to capitalize the third phe-
nomenon, allowing survival and growth.
The physiological environments of solid tumors differ from that of
normal tissues in many ways: it is hypoxic, low in pH and low in nutri-
ents [4]. These environmental factors all contribute to the activation of
ER stress and as a result, cancerous cells must possess ways to adapt
and prevent the fate of ER stress-induced apoptosis [2,5]. Recent studies
have shown the various ways in which cancerous cells utilize altered
states of ER stress responses in order to perturb ER associated cell
death signaling. The following reviewwill look at some of these studies,
ER stress associated responses and their components, as well as
targeting these pathways for developing cancer treatments.
2. Endoplasmic reticulum stress
The ER functions to regulate the quality, folding and secretion of
newly synthesized proteins. Under normal conditions, correctly folded
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lular location. If proteins are misfolded, they are retained in the ER for
further processing by ER protein chaperones, such as calreticulin,
calnexin and endoplasmic reticulum protein 57 (ERp57), until they
attain the correct conformation for secretion. However, if the correct
conformation cannot be achieved, the misfolded protein is sent for
ER-associated degradation (ERAD).When environmental factors greatly
perturb these processes that maintain ER homeostasis, the ER un-
dergoes stress and activates various ER stress responses termed as the
unfolded protein response (UPR).
2.1. Unfolded protein response
The UPR is composed of three different pathways that fall under the
control of three respective ER transmembrane proteins: protein kinase
RNA-like endoplasmic reticulum kinase (PERK), inositol-requiring
enzyme 1α (IRE1α) and activating transcription factor 6 (ATF6) [6–8].
Under normal cellular conditions, PERK, IRE1α and ATF6 form stable
complexes with the ER stress sensor binding immunoglobulin protein
(BiP) and remain in their inactive state [9]. BiP binds to the ER luminal
domains, preventing homodimerization and activity of PERK and
IRE1α [10,11]. The binding of BiP to ATF6 blocks its Golgi-localization
signals, retaining ATF6 to the ER membrane, which prevents further
processing of ATF6 to its active form [8,12]. In the presence of cellular
stress, accumulation of misfolded proteinswithin the ER binds BiP com-
petitively, causing dissociation of BiP from PERK, IRE1α and ATF6, thus
removing its inhibitory effects [9,10,12]. Release of BiP allows PERK to
dimerize and subsequently autophosphorylate, turning on its kinase ac-
tivity [10]. Activated PERK phosphorylates and inhibits the eukaryotic
initiation factor 2α (eIF2α), consequently turning off protein synthesis
but selectively increasing expression of ATF4 and C/EBP homologous
protein (CHOP) [7,10,13]. ATF4 is a transcription factor that regulates
pro-survival genes, such as those involved in oxidative stress, amino
acid synthesis, protein folding and differentiation [14]. Similarly, upon
dissociation from BiP, IRE1α undergoes dimerization and autophospho-
rylation, activating its endonuclease activity for mRNA processing
[10,15–19]. A particularly important target of IRE1α is the mRNA
encoding X-box binding protein 1 (XBP1). IRE1α splices a 26 base pair
region from the XBP1 mRNA, resulting in an active XBP1 transcription
factor which functions to up-regulate gene encoding proteins involved
in protein folding, quality control and ERAD [19]. In the case of ATF6,
the release of BiP unmasks its Golgi-localization signals, which allows
ATF6 to translocate to the Golgi. ATF6 is then sequentially cleaved by
the site-1 and site-2 proteases, releasing an N-terminal fragment that
acts as a transcription factor to increase transcription of XBP1 and
ERAD associated proteins [12,19,20].
2.2. Apoptosis
Under moderate ER stress, the UPR can function as a pro-survival
mechanism and return the cell to its state of homeostasis. However,
when cellular damage exceeds the capacity of this adaptive response,
ER stress is prolonged and continued activation of the UPR signals the
cell for apoptosis [21,22]. CHOP is a major pro-apoptotic transcription
factor that mediates ER-stress induced apoptosis and is a target for up-
regulation by all three arms of the UPR pathway [23]. CHOP induces
cell death through regulating expression of various genes. In particular,
CHOP suppresses expression of the anti-apoptotic B-cell lymphoma-2
(Bcl-2) protein, which increases production of reactive oxygen species
and causes injury to the cell [22,24]. Furthermore, CHOP increases the
burden of misfolding in the ER by re-establishing protein folding and it
increases the expression of growth arrest and DNA damage-inducible
protein (GADD34), a regulatory subunit of protein phosphatase 1
(PP1), which allows dephosphorylation and activation of eIF2α [25].
CHOP induces ER oxidoreductin 1α (ERO1α), hyperoxidizes the ER en-
vironment and further commits the cell to apoptosis [25].Activated IRE1α binds tumor necrosis factor (TNF) receptor associ-
ated factor 2 (TRAF2) through its cytosolic domain, recruiting apoptotic
signal-regulating kinase 1 (ASK1) into complex formation and commu-
nicating ER stress by c-JUN amino-terminal kinase (JNK) activation, a
major mediator of apoptosis [26,27]. The association of IRE1α to
TRAF2 also leads to clustering, cleavage and activation of caspase 12, an-
other pro-apoptotic protein that responds only to ER stress [28,29].
There is currently much discrepancy in the activation and role of cas-
pase 12 between humanand rodent [30]. Although further investigation
is needed to conﬁrm the above pathway in humans and rodents, cas-
pase 12 likely plays a role in ER-stress induced apoptosis through inhib-
itory effects on NF-κB, a transcription factor involved in the immune
response and apoptosis [31].
Lastly, additional targets of the IRE1αRNase activity have been found
[15,17,32,33]. Apart from XBP1 splicing, activated IRE1α is also respon-
sible for regulated IRE1α dependant decay (RIDD) ofmanymRNAs asso-
ciatedwith theER [15,17]. RIDDplays an important factor in thedecision
for cellular apoptosis and induction of XBP1 splicing by IRE1α in the
absence of RIDD activity increased cellular survival against tunicamycin
induced ER stress and apoptosis [34]. Moreover, IRE1αmay cause cleav-
age of selective microRNAs responsible for repression of caspase-2
mRNA translation, and this enhances the level of caspase-2 expression
resulting in cellular apoptosis [32]. However, the role of ER stress in ac-
tivation of caspase-2 to initiate apoptosis has been recently challenged
[35]. MiR-17, a thioredoxin-interacting protein destabilizing microRNA,
is another microRNA target of IRE1α RNase activity and implicates the
role of IRE1α in inﬂammation and programmed cell death induced by
prolonged UPR activity [33].
3. Cancer
The dualistic response of the UPR initiated by ER stress initially
serves as an adaptive measure to protect the cell from irreversible dam-
age.When this damage becomes too great, theUPR then becomes a self-
destructive signal to rid the organism of the diseased cell and prevent
further toxicity. The metabolic condition of cancer, being highly prolif-
erative under a low vascularized state, creates an unfavorable microen-
vironment consisting of low pH, low oxygen, and low glucose and other
nutrient supply [4]. Low glucose availability affects protein glycosyla-
tion and ATP production leading to accumulation of misfolded proteins
within the ER [36]. As well in hypoxic conditions, lack of oxygen puts a
demand on protein folding, as oxygen is an electron carrier required for
disulphide bond formations, contributing to protein misfolding [37].
Under normal conditions, these are all factors that contribute to ER
stress mediated cell death, but cancer cells have evolved ways to
adapt to this environmental stress and escape the fate of apoptosis.
3.1. GRP78/BiP
The ER protein chaperone BiP, also known as 78-kDa glucose-
regulated protein (GRP78), plays a major role in the adaptive response
to ER stress and is commonly found to be highly expressed in breast
cancer, lung cancer, prostate cancer and other malignancies [38–42].
The elevated expression of BiP plays a major role in the pro-survival
and cytoprotective response of cancer cells to major environmental
stress through a variety of mechanisms. Overexpression of BiP was
found to protect human breast cancer cells from estrogen-starvation in-
duced apoptosis through complex formation and inhibition of BIK, a
pro-apoptotic BH3-protein [43]. The ATP binding site of BiP was found
to interact with and suppress the activation of caspase-7, preventing
apoptotic induction by topoisomerase inhibitors such as etoposide,
doxorubicin and camptothecin [44]. Recently, it has been found that
clusterin, an ER-stress induced protein chaperone, promotes survival
of hepatocellular carcinoma cells under extreme ER stress through in-
teractions with and increased expression of BiP [45]. In contrast, mole-
cules that bind to and inhibit BiP increase cellular susceptibility to ER
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small interfering RNA (siRNA) in HeLa cells, expression of GRP94,
CHOP, ERdj4 and P5 increased, suggesting that another mechanism by
whichBiP prevents cell death is regulation of theUPR [47]. Furthermore,
BiP is positively regulated by the mitogen-activated protein kinase
(MAPK) pathway. Inhibition of the MAPK pathway in melanoma cells
decreased expression of BiP, resulting in increased caspase-4 mediated
ER-stress induced apoptosis [48].
The study of BiP in cancer has increased signiﬁcantly and has proven
to be a highly relevant therapeutic target. Many anticancer treatments
function through activation of ER stress and as a result, induce BiP activ-
ity. BiP activation has been shown to contribute to resistance of cancer
to these anti-cancer therapies. As previously mentioned, BiP expression
plays a role in chemoresistance to topoisomerase inhibitors and subse-
quently, examining BiP expression in breast cancer prior to treatment
can predict the prognosis of chemotherapy [44,49]. On the other hand,
BiP expression is a positive indicator of therapeutic beneﬁt from adju-
vant chemotherapy in patients with colorectal cancer and this discrep-
ancy may be due to differences in treatment or tissue [50]. In addition
to acting as a biomarker for predicting treatment outcomes, BiP can be
targeted for inhibition during traditional anti-cancer therapy to reduce
its cytoprotective effects. Subtilase cytotoxin catalytic subunit fused
with epidermal growth factor (EGF-SubA) is a BiP inhibitor and when
used to treat cancer cells during photodynamic therapy, can prevent
BiP mediated resistance [51]. Similarly, gastric cancer multidrug resis-
tance cell-speciﬁc binding peptide (GMBP1) binds the surface of gastric
cancer cells and preventsmultidrug resistance through interactingwith
and decreasing expression of BiP [52].
3.2. IRE1α and XBP1
The role of IRE1α and XBP1 signaling has been investigated in solid
tumors, breast cancer, hepatocellular carcinoma and multiple myeloma
[2,53,54]. XBP1 is amajor transcriptional factor involved in the adaptive
response to ER stress and is required for solid tumor growth and
survival under hypoxic stress [55]. An increase in XBP1 expression and
splicing was observed in hepatocellular carcinoma and breast cancer,
which may result from the regulatory function of XBP1 towards BiP
[56,57].
Numerous reports have shown the importance of the IRE1α and
XBP1 signaling pathway in multiple myeloma [54]. Notably, XBP1 is
overexpressed in plasma cells from myeloma and is an important tran-
scription factor known to be required for plasma cell differentiation
[58–61]. The overexpression of XBP1 may be a critical component that
induces multiple myeloma [61]. Blimp-1, another transcription factor
involved in plasma cell differentiation functions upstream of and up-
regulates XBP1 which in turn induces the secretory pathway, enlarges
the size of the ER and increases protein synthesis [60]. Furthermore,
IRE1α induces cellular proliferation through XBP1 splicing, increasing
expression of genes that encode for ER-Golgi, plasmamembrane, secre-
tory proteins and in particular, cyclin A1 a cell cycle regulatory protein
[62]. In addition, the IRE1α-XBP1 pathway appears to be regulated by
a family of Bcl-2 proteins. BAX and BAK were necessary to activate
IRE1α through a direct interaction with the cytosolic domain [63]. Bim
and PUMA were also identiﬁed as IRE1α interacting Bcl-2 family pro-
teins that modulate XBP1 splicing activity [64]. These studies suggest a
direct association between theUPR and the apoptotic pathway and pro-
vide a new regime in cancer therapy.
Studies indicate that the IRE1α-XBP1 pathway is amajor therapeutic
target in treatment of cancer, more prominently in multiple myeloma
[65]. Inhibition of XBP1 splicing byMKC-3946 reduced growth of multi-
plemyeloma cells and enhanced the pro-apoptotic effects of drugs such
as Bortezomib and 17-AAG [66]. Speciﬁc inhibition of IRE1α endonucle-
ase activity by STF-083010 sensitized multiple myeloma cells to ER
stress and reduced survival [67]. A small molecule, 4u8C, that binds
and blocks the active site of IRE1α RNase activity inhibited XBP1splicing and RIDD leading to disrupted ER mediated expansion and se-
cretion [68]. Another inhibitor, toyocamycin, was found to speciﬁcally
target and prevent splicing of XBP1 by IRE1α, inhibiting XBP1 expres-
sion and induction through ER stress [69]. Analogs of 4-phenylbutyric
acid that inhibit IRE1α and XBP1 splicing have been developed and
show strong therapeutic promise in their ability to block IRE1α signal-
ing pathways [70].
3.3. PERK, eIF2α and ATF4
The activity of the PERK/eIF2α pathway contributes greatly to the
growth and survival of cancer under hypoxic stress [2,71]. Hypoxia
has been shown to greatly down-regulate protein synthesis through
an increase in PERK inhibition and phosphorylation of eIF2α at Ser51.
When the PERK/eIF2α pathway is abolished, whether through PERK
knockout or transfection with mutant alleles of PERK or eIF2α, the
cells experienced a decrease in protein synthesis inhibition and toler-
ance to hypoxic conditions [72,73]. Moreover, a microarray analysis of
PERK+/+ and PERK−/−mouse embryonic ﬁbroblasts under aerobic and
hypoxic conditions revealed mechanistically that PERK is responsible
for activation of many angiogenic genes as well as an adhesion protein,
vascular endothelial growth factor (VEGF) and type 1 collagen inducible
protein [74].
While PERK inhibits general protein synthesis through eIF2α phos-
phorylation, there is still active translation of ATF4, a transcription factor
that regulates pro-survival genes, such as those involved in oxidative
stress, amino acid synthesis, protein folding and differentiation
[2,75,76]. ATF4 is overexpressed in many human solid tumors and is in-
volved in promoting proliferation and survival of nutrient deprivation
through regulating expression of asparagine synthetase [77]. Another
mechanism by which ATF4 expression contributes to cancer formation
is through negatively regulating genes involved in cellular senescence,
while ATF4 repression inducing cellular senescence and preventing
oncogenic transformation [78]. Furthermore, ATF4 mediates survival
during severe hypoxia through up-regulation of LC3B [79]. LC3B is a
component of the autophagosomal membrane, and up-regulation
induces autophagy, a process by which cells increase lysosomal degra-
dation of unnecessary cellular components, thereby conserving energy
for survival under nutrient deprivation [79]. As well, the lysosomal-
associated membrane protein 3 (LAMP3), which promotes hypoxia-
driven metastasis, is highly expressed in primary human cervix tumors
and is induced through the PERK/ATF4 pathway [80]. Lastly, induction
of tumorigenesis by forced expression of myc, a transcription factor
that controls cell growth and protein synthesis, requires activation of
theUPR [81]. Myc-transformed cells create intrinsic stress, such as accu-
mulation of unfolded proteins, which under normal conditions, lead to
cell death. Activation of UPR is therefore necessary to deal with myc-
induced stress, by activation of autophagy through the PERK/eIF2α/
ATF4 pathway [81,82].
Hypoxia is a very common stress factor in cancer and as a result, the
PERK/eIF2α/ATF4 pathway is a highly promising therapeutic target.
When compared with inhibition of IRE1α signaling, the PERK inhibitor,
GSK-compound 39 was more effective in reducing adaptation and
survival of cells to hypoxia-induced ER stress [83]. A potent and selective
inhibitor of PERK activity, GSK2606414, was found to reduce tumor
growth in vitro and in vivo as demonstrated in cells and human tumor
xenographs inmice [84]. Similarly, GSK2656153, an ATP-competitive in-
hibitor of PERK, also exhibits anti-tumor effects, inhibiting growth of
human tumor xenographs in mice in a dosage dependant manner [85].
Moreover, the role of the PERK/eIF2α/ATF4 pathway in cancer progres-
sion is mediated by various mechanisms which can all be targeted for
therapeutic development. For example, sinulariolide, an effective anti-
tumor compound used to kill melanoma and bladder cancer cells,
works through activation of the PERK/eIF2α/ATF4/CHOP apoptotic path-
way [86]. The nonsteroidal anti-inﬂammatory drug tolfenamic acid sup-
presses progression of colorectal cancer cells through promotion of ER
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when the PERK/ATF4/LAMP3 pathway was inhibited, the DNA-damage
response was disrupted and breast cancer cells were sensitized to radio-
therapy [88]. More recently, the active, Ser 245 phosphorylated ATF4
was found to be overexpressed in non-small cell lung cancer cells and
could be further investigated as a potential biological marker for cancer
[89].
3.4. ATF6
In comparison with the PERK and IRE1α pathway, there have been
fewer studies on ATF6 in association with cancer. Nevertheless, it has
been shown that ATF6 does play a role in human cancers, that its expres-
sion is necessary for malignancy and that this is mainly dependant on
interaction with the other arms of the UPR [54]. In a recent study, a mis-
sense single nucleotide polymorphism (SNP) was identiﬁed in the ATF6
gene, correlating with a decrease in ATF6 mRNA and ATF6 target gene
expression, contributing to an increase in hepatocellular carcinoma sus-
ceptibility [90]. When ATF6 is knocked down in multiple myeloma cells,
PERK phosphorylation of eIF2α increases, which suppressed apoptosis
and induced autophagy [54,91]. Furthermore, ATF6 is responsible for
up-regulation of XBP1 expression [19] and the activity of both pathways
increases BiP expression, which is required for hepatocarcinogenesis [57].
The signaling pathway of ATF6 and its relation to the other two UPR
pathways may be complex and worth investigating as a target for anti-
cancer treatment. In a study that looked at the dependence of pancreatic
β-cells on active ATF6-p50 expression under non-stressed conditions,
knockdown of ATF6-p50 induced apoptosis through phosphorylation
of JNK, p38 and c-Jun [92]. SiRNA induced knockdown of C16-ceramide
was found to activate ATF6, increasing CHOP expression and leading








Fig. 1. ER stress and cancer. Under mild ER stress, the UPR is activated to copewith the disturba
cell. Studies have shown that an altered state of the UPR acts as a driver ofmalignancy but in oth
nutrient deprivation and low pH). The UPR can therefore become a target for anti-cancer theraneck squamous cell carcinomas [93]. ATF6α expression was shown to
enhance tumor cell survival through increased expression and activity
of a cell surviving Rheb-mTOR signaling pathway [94].Whilemost stud-
ies show that ATF6 promotes survival in cancer, in myoblast cells, over-
expression of ATF6 caused apoptosis. This occurs through an increased
expression of pro-apoptotic WW domain binding protein 1 and sup-
pression of the anti-apoptotic protein, myeloid cell leukemia sequence
1 [95]. The contradiction in ATF6 function in cancer may be due to the
difference in ATF6 isoforms.
3.5. Sigma-1 receptor
The sigma-1 receptor is an ER protein chaperone up-regulated in
many human cancer cell lines [96]. Importantly, the sigma-1 receptor
interacts with other ER protein chaperones like BiP and IRE1α at mito-
chondria associated membranes (MAMs), a speciﬁc region of the ER
where the membrane may connect directly to the mitochondria [97].
The gathering of sigma-1 receptors at MAMs allows for the receptors
to efﬁcientlymodulate cell survival signals from the ER to themitochon-
dria. When ER calcium is depleted, BiP dissociates from the sigma-1 re-
ceptor, enabling its function to stabilize inositol 1,4,5-triphosphate
receptors at MAMs and facilitate calcium signaling to the mitochondria
[97]. Additionally, under ER stress conditions, the sigma-1 receptor was
also found to interact with and stabilize IRE1α at MAMs and enhance
cellular survival through prolonged activation of the IRE1α-XBP1 path-
way [98].
Increased expression of the sigma-1 receptor promotes the adaptive
response against ER stress, while a decreased expression leads to apo-
ptosis [97]. Inhibitors of the sigma-1 receptor may become promising
therapeutic targets in cancer. Antagonists that inhibit sigma-1 receptor










nce in homeostasis, however when ER stress is prolonged apoptosis is activated to kill the
er cases cancers alter the state of the UPR to adapt to its environmental stress (i.e. hypoxia,
py, with a focus on how to activate the apoptotic pathway.
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knockdown of sigma-1 receptors reduced tumor cell mass through
translational repression, revealing a role for sigma-1 receptors in protein
synthesis and providing a new avenue for anti-cancer therapy [100].
3.6. ERAD
Maintaining homeostasis between protein synthesis and degrada-
tion is another important factor of normal cellular metabolism. ERAD
is an integral part of the ER stress response responsible for the degrada-
tion of excess ormisfolded intracellular proteins. By itself, the disruption
of ERAD or the balance between protein synthesis and degradation can
lead to accumulation of misfolded proteins, cytotoxicity, ER stress and
eventual apoptosis. Therefore the effect of ERAD on ER stress and ER
stress mediated apoptosis has been utilized in the development of po-
tent anti-cancer drug treatments [65,101]. Proteasome inhibitors such
as MG-132 and Bortezomib can elicit a strong stress response followed
by apoptosis and speciﬁcally, Bortezomib has shown potential in clinical
trials against non-Hodgkin lymphoma, acute myeloid leukemia and
multiple myeloma [102–104]. In combination with Bortezomib, treat-
ment with ER stress inducer celebrex or ERAD inhibitor Eeyarestatin I
enhances the antitumor activity of Bortezomib and reveal the additive
toxicity of ERAD inhibition with ER stress [105,106].
The AAA ATPase molecular chaperone valosin containing protein
(VCP) or p97 has been shown to be up-regulated in many different
types of cancer andmay become a potential target in anticancer therapy
[107]. VCP is involved in a wide variety of biological functions such as
protein folding, cell cycle control and apoptosis but as a part of ERAD,
it controls ubiquitin mediated degradation of misfolded proteins
[107]. Development of VCP inhibitors has come under way and many
are potential candidates in treatment of cancer. Eeyarestatin I, as men-
tioned above, is an ERAD inhibitor and functions through interaction
with VCP, blocking its protein degradation activity [108]. VCP inhibition
with Eeyarestatin I suppressed tumor growth and induced apoptosis in
non-small cell lung carcinoma in vitro and in xenograft murine models
[109]. DBeQ is a potent small molecule inhibitor of VCP that targets its
ATPase activity and is effective in suppressing tumor growth and acti-
vating caspase-3 and caspase-7 in executing apoptosis [110]. Lastly, a
novel group of allosteric VCP inhibitors, alkylsulfanyl-1,2,4-triazoles,
were identiﬁed and may be further developed as a basis for future can-
cer therapy drugs [107].
4. Conclusion
Cancer cells deviate from normal cells in many aspects: they are
highly proliferative, anaerobic and they often outgrow their blood sup-
ply. These physiological differences result in a tumormicroenvironment
that is hypoxic, low in nutrients and low in pH, factors that can cause re-
sistance to anti-cancer therapy [4]. This microenvironment is unfavor-
able to cancer cells because it causes ER stress, a phenomenon that if
prolonged, can lead to cell death through apoptosis (Fig. 1). Before trig-
gering apoptosis, ER stress activates a number of adaptive responses,
termed the UPR, to bring the cell back to homeostasis. Many human
cancers have alterations in the UPR, and can therefore adapt to chronic
stress and avoid cell death. Whether changes in the UPR are the driving
force of or a consequence of malignancy is still unknown but compo-
nents of the UPR may become a useful therapeutic target for anti-
cancer therapies (Fig. 1).
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